Literature DB >> 28829758

Catastrophic antiphospholipid syndrome (Ronald Asherson syndrome) and obstetric pathology.

Alexander D Makatsariya1, Jamilya Khizroeva2, Viktoriya O Bitsadze2.   

Abstract

BACKGROUND: Catastrophic antiphospholipid syndrome (CAPS) is an uncommon, often fatal, variant of the antiphospholipid syndrome (APS) that results in a widespread coagulopathy and high titres of antiphospholipid antibodies (aPL) and affects predominantly small vessels supplying organs with the development of multiorgan failure. It remains unclear why some patients develop the typical clinical picture of APS (thrombosis of large vessels), whereas others show the development of progressive microthrombosis, which the authors called "thrombotic storm" and multiple organ failure, that is, CAPS.
MATERIALS AND METHODS: Since 2001-2016, we discovered 17 patients with CAPS development.
CONCLUSION: CAPS is life-threatening condition, but optimal treatment for CAPS is not developed yet and the mortality rate is as high as 30%-40%.

Entities:  

Keywords:  Antiphospholipid syndrome; catastrophic APS; rare disease; thrombotic storm

Mesh:

Year:  2018        PMID: 28829758     DOI: 10.1515/jpm-2017-0092

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  2 in total

1.  Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review.

Authors:  Melody Hermel; David Hermel; Saif Azam; Jerold Shinbane; Annahita Sarcon; Erika Jones; Arjun Mehta; Luanda Grazette; Howard Liebman; Ilene Weitz
Journal:  EJHaem       Date:  2020-07-31

Review 2.  Catastrophic antiphospholipid syndrome during pregnancy.

Authors:  Marta Fuentes Carrasco; Alejandra Mayoral Triana; Ignacio Cristóbal Cristóbal García; Noelia Pérez Pérez; Nuria Izquierdo Méndez; Patricia Soler Ruiz; Virginia González González
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2021-07-07       Impact factor: 2.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.